Long-term Efficacy of Doxazosin Plus Atenolol in the Management of Severe and Sustained Arterial Hypertension and Reversibility of the Cardiac Damage Induced by Chronic Cathecolamine Excess. A Case Report in a Young Girl with Recurrent, Functioning...

Overview

Journal J Endocrinol Invest

Publisher Springer

Specialty Endocrinology

Date 2005 Jan 8

PMID 15636433

Authors

M Pulcrano

E A Palmieri

L Pagano

L Tauchmanova

A Rossi

S Fazio

G Lombardi

B Biondi

Affiliations

Soon will be listed here.

Abstract

Herein we report on a young girl with recurrent, functioning paraganglioma of the organ of Zuckerkandl and severe and sustained arterial hypertension (systolic pressure >200, diastolic pressure >120 mmHg); with evidence of cardiac damage induced by chronic cathecolamine excess. She promptly and steadily improved after the institution of doxazosin (6 mg/day) plus atenolol (50 mg bid) treatment. This case demonstrates that a correct therapeutic strategy in the long-term management of patients with inoperable catecholamine-producing neuroendocrine tumors (pheochromocytomas and paragangliomas) can maintain arterial pressure in the normal range and reverse the cardiac damage induced by chronic cathecolamine excess.

References

Farndon J . Efficacy and safety of doxazosin for perioperative management of patients with pheochromocytoma. World J Surg. 2002; 26(8):1037-42. DOI: 10.1007/s00268-002-6667-z. View

Pacak K, Linehan W, Eisenhofer G, Walther M, Goldstein D . Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med. 2001; 134(4):315-29. DOI: 10.7326/0003-4819-134-4-200102200-00016. View

Hoefnagel C . Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumours. Eur J Nucl Med. 1994; 21(6):561-81. DOI: 10.1007/BF00173045. View

Bravo E . Evolving concepts in the pathophysiology, diagnosis, and treatment of pheochromocytoma. Endocr Rev. 1994; 15(3):356-68. DOI: 10.1210/edrv-15-3-356. View

Sisson J, Frager M, Valk T, Gross M, Swanson D, Wieland D . Scintigraphic localization of pheochromocytoma. N Engl J Med. 1981; 305(1):12-7. DOI: 10.1056/NEJM198107023050103. View

Erickson D, Kudva Y, Ebersold M, Thompson G, Grant C, Van Heerden J . Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients. J Clin Endocrinol Metab. 2001; 86(11):5210-6. DOI: 10.1210/jcem.86.11.8034. View

Taylor S . Efficacy of doxazosin in specific hypertensive patient groups. Am Heart J. 1991; 121(1 Pt 2):286-92. DOI: 10.1016/0002-8703(91)90859-g. View

Russell W, Metcalfe I, Tonkin A, Frewin D . The preoperative management of phaeochromocytoma. Anaesth Intensive Care. 1998; 26(2):196-200. DOI: 10.1177/0310057X9802600212. View

Bravo E . Pheochromocytoma: new concepts and future trends. Kidney Int. 1991; 40(3):544-56. DOI: 10.1038/ki.1991.244. View

10.

Bravo E, Tagle R . Pheochromocytoma: state-of-the-art and future prospects. Endocr Rev. 2003; 24(4):539-53. DOI: 10.1210/er.2002-0013. View

11.

Navaratnarajah M, White D . Labetalol and phaeochromocytoma. Br J Anaesth. 1984; 56(10):1179. DOI: 10.1093/bja/56.10.1179. View

12.

Stenstrom G, Svardsudd K . Pheochromocytoma in Sweden 1958-1981. An analysis of the National Cancer Registry Data. Acta Med Scand. 1986; 220(3):225-32. View

13.

Bender B, Altehofer C, Januszewicz A, Gartner R, Schmidt H, Hoffmann M . Functioning thoracic paraganglioma: association with Von Hippel-Lindau syndrome. J Clin Endocrinol Metab. 1997; 82(10):3356-60. DOI: 10.1210/jcem.82.10.4050. View

14.

Neumann H, Bausch B, McWhinney S, Bender B, Gimm O, Franke G . Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med. 2002; 346(19):1459-66. DOI: 10.1056/NEJMoa020152. View

15.

Kwekkeboom D, van Urk H, Pauw B, Lamberts S, Kooij P, Hoogma R . Octreotide scintigraphy for the detection of paragangliomas. J Nucl Med. 1993; 34(6):873-8. View

16.

Miura Y, Yoshinaga K . Doxazosin: a newly developed, selective alpha 1-inhibitor in the management of patients with pheochromocytoma. Am Heart J. 1988; 116(6 Pt 2):1785-9. DOI: 10.1016/0002-8703(88)90230-x. View